Citations

Mayo Clinic

Showing 10 of 108551 citations.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, Pieter , Avet‐Loiseau, Hervé , Usmani, Saad Z. , Moreau, Philippe , Attal, Michel , Kyle, Robert A. , Caers, Jo , Hillengaß, Jens , Miguel, Jesús F. San , Donk, Niels W.C.J. van de , Bladé, Joan , Durie, Brian G.M. , Goldschmidt, Hartmut , Mateos, María‐Victoria , Palumbo, Antonio , Orlowski, Robert Z. , Lonial, Sagar , Siegel, David S. , Anderson, Kenneth C. , Chng, Wee Joo , Einsele, Hermann , Orlowski, Robert Z. , Moreau, Philippe , San-Miguel, Jesus , Usmani, Saad

Blood | March 22, 2016 | Volume: 127 | Issue: 24 | Pages: 2955-2962

10.1182/blood-2016-01-631200 | PMID 27002115 Get It

AbstractThe International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.
Intravenous Proton Pump Inhibitors before Endoscopy in Bleeding Peptic Ulcer with High-Risk Stigmata: A Multicentre Comparative Study
Andrews, Christopher N. , Levy, Adrian R., Fishman, Martin, Hahn, Michael , Atkinson, Kenneth, Kwan, P., Enns, Robert , Andrews, Christopher N

Canadian Journal of Gastroenterology | March 21, 2016 | Volume: 19 | Issue: 11 | Pages: 667-671

10.1155/2005/476205 | PMID 16292361 Get It

BACKGROUND: It is not clear if starting intravenous proton pump inhibitors (IV PPI) before endoscopic therapy provides additional benefit over starting it afterward in patients with high-risk ulcer stigmata of peptic ulcer disease.METHODS: All patients who received IV pantoprazole bolus and infusion and underwent endoscopy in six Canadian hospitals over 20 months were reviewed. Only patients with high-risk ulcer stigmata (arterial bleeding, oozing, nonbleeding visible vessel or adherent clot) were included. Patients receiving IV PPI before endoscopy (before group) were compared with those who received it after endoscopy (after group) with respect to endoscopic findings and, secondarily, to patient demographics and clinical outcomes.RESULTS: The demographics and baseline characteristics of the before group (n=57) and the after group (n=109) were similar. The before group was more likely to have had IV PPI started outside of daytime hours, and median time to endoscopy in patients admitted with upper gastrointestinal bleeding was 24 h (interquartile range 9.5 to 35) in the before group and 11.3 h (interquartile range 3.7 to 17.2) in the after group ( P<0.0001). At the time of endoscopy, 33% of patients in the before group had actively bleeding lesions (Forrest 1a or 1b) compared with 54% in the after group (P=0.01), but there were no significant differences in rebleeding, surgical rates, intensive care unit admission or death between the groups.CONCLUSION: IV PPI infusions before endoscopy may lower the proportion of actively bleeding peptic ulcer lesions at endoscopy, but this finding does not appear to affect rates of rebleeding, surgery or death.
Response to Letter Regarding Article, “Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review”
Asif, Irfan M. , Maleszewski, Joseph J. , Owens, David S. , Prutkin, Jordan M. , Salerno, Jack C., Ellenbogen, Rachel, Rao, Ashwin L., Ackerman, Michael J. , Harmon, Kimberly G. , Suchsland, Monica Zigman , Drezner, Jonathan A.

Circulation | March 21, 2016 | Volume: 133 | Issue: 12 | Pages: No page available

10.1161/circulationaha.116.020661 | PMID 27002088 Get It

Impact of Socioeconomic Status, Ethnicity, and Urbanization on Risk Factor Profiles of Cardiovascular Disease in Africa
Sliwa, Karen , Acquah, Letitia, Mocumbi, Ana Olga , Gersh, Bernard J. , Sliwa, K

Circulation | March 21, 2016 | Volume: 133 | Issue: 12 | Pages: 1199-1208

10.1161/circulationaha.114.008730 | PMID 27002082 Get It

Africa is a continent characterized by marked ethnic, sociodemographic, and economic diversity, with profound changes in many regions over the past 2 decades. This diversity has an impact on cardiovascular disease presentation and outcomes. Within Africa and within the individual countries, one can find regions having predominantly communicable diseases such as rheumatic heart disease, tuberculous pericarditis, or cardiomyopathy and others having a marked increase in noncommunicable disease such as hypertension and hypertensive heart disease. Ischemic heart disease remains rare in most countries. Difficulties in the planning and implementation of effective health care in most African countries are compounded by a paucity of studies and a low rate of investment in research and data acquisition. The fiduciary responsibilities of companies working in Africa should include the effective and efficient use of natural resources to promote the overall health of populations.
Validation of the 17‐item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impressi
Angleró, Gabriela C., Jenkins, Gregory D. , Hall‐Flavin, Daniel K., Weinshilboum, Richard M. , Bobo, William V. , Jenkins, Gregory, Hall-Flavin, Daniel K, Weinshilboum, Richard, Weinshilboum, Richard M. , Biernacka, Joanna M.

Human Psychopharmacology: Clinical and Experimental | March 21, 2016 | Volume: 31 | Issue: 3 | Pages: 185-192

10.1002/hup.2526 | PMID 26999588 Get It

Objective The study aimed to define thresholds of clinically significant change in 17‐item Hamilton Depression Rating Scale (HDRS‐17) scores using the Clinical Global Impression‐Improvement (CGI‐I) Scale as a gold standard. Methods We conducted a secondary analysis of individual patient data from the Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study, an 8‐week, single‐arm clinical trial of citalopram or escitalopram treatment of adults with major depression. We used equipercentile linking to identify levels of absolute and percent change in HDRS‐17 scores that equated with scores on the CGI‐I at 4 and 8 weeks. Additional analyses equated changes in the HDRS‐7 and Bech‐6 scale scores with CGI‐I scores. Results A CGI‐I score of 2 (much improved) corresponded to an absolute decrease (improvement) in HDRS‐17 total score of 11 points and a percent decrease of 50–57%, from baseline values. Similar results were observed for percent change in HDRS‐7 and Bech‐6 scores. Larger absolute (but not percent) decreases in HDRS‐17 scores equated with CGI‐I scores of 2 in persons with higher baseline depression severity. Conclusions Our results support the consensus definition of response based on HDRS‐17 scores ( > 50% decrease from baseline). A similar definition of response may apply to the HDRS‐7 and Bech‐6. Copyright © 2016 John Wiley & Sons, Ltd.
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Dubois, Bruno , Hampel, Harald , Feldman, Howard , Scheltens, Philip , Aisen, Paul, Andrieu, Sandrine , Bakardjian, Hovagim , Benali, Habib , Blennow, Kaj , Broich, Karl , Cavedo, Enrica , Crutch, Sebastian J. , Dartigues, Jean‐François , Duyckaerts, Charles , Frisoni, Giovanni B. , Gauthier, Serge , Genthon, Rémy, Gouw, Alida A. , Habert, Marie‐Odile , Lista, Simone , Molinuevo, José Luís , O’Bryant, Sid E. , Rabinovici, Gil D. , Salloway, Stephen , Schneider, Lon S. , Teichmann, Marc , Carrillo, María C. , Jack, Cliff R, Jack, Clifford R. , Frisoni, Giovanni B. , Bertram, Lars , Epelbaum, Stéphane , Holtzman, David M. , Kivipelto, Miia , Rowe, Christopher Cleon , Sperling, Reisa Anne , Cummings, Jeffrey L. , Jack, Clifford R , Scheltens, Philip , Molinuevo, José Luis , Rabinovici, Gil D , Feldman, Howard H , O'Bryant, Sid

Alzheimer's & Dementia | March 21, 2016 | Volume: 12 | Issue: 3 | Pages: 292-323

10.1016/j.jalz.2016.02.002 | PMID 27012484 Get It

Abstract During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Evaluation of Patient Tolerance and Small-Bowel Distention With a New Small-Bowel Distending Agent for Enterography
Kolbe, Amy B. , Froemming, Adam T. , Sheedy, Shannon P. , Koo, Chi Wan , Pundi, Krishna , Bruining, David H. , Harmsen, William S. , Barlow, John M. , Fidler, Jeff L. , Tung, Jeanne , Fletcher, Joel G. , Fidler, Jeff L. , Pundi, Krishna

American Journal of Roentgenology | March 21, 2016 | Volume: 206 | Issue: 5 | Pages: 994-1002

10.2214/ajr.15.15260 | PMID 26998661 Get It

The Challenges of Stroke Prediction Scores
Nasr, Deena M. , Brown, Robert D.

JAMA Neurology | March 21, 2016 | Volume: 73 | Issue: 5 | Pages: 510

10.1001/jamaneurol.2016.0289 | PMID 26999800 Get It

Motion – All Patients with NASH Need to Have a Liver Biopsy: Arguments for the Motion
Talwalkar, Jayant A.

Canadian Journal of Gastroenterology | March 20, 2016 | Volume: 16 | Issue: 10 | Pages: 718-721

10.1155/2002/759701 | PMID 12420034 Get It

Previously regarded as an obscure disorder, nonalcoholic steatohepatitis (NASH) has recently emerged as an important chronic liver disease. NASH is within a spectrum of disorders characterized by excessive accumulation of fat in the liver, including simple hepatic steatosis (fatty liver), inflammation and necrosis (steatohepatitis), and fibrosis. Collectively, the disorders are called nonalcoholic fatty liver disease (NAFLD). Estimates of the prevalence of these individual conditions are suspect because liver biopsy is required for definitive diagnosis and is not generally performed. Although these conditions have traditionally been thought of as diseases of obese women, and are frequently associated with diabetes mellitus and hypertriglyceridemia, they have also been identified in lean men. Insulin resistance appears to be a common factor. These conditions are difficult to distinguish from each other clinically, and no biochemical or radiological test reliably establishes the diagnosis. A ratio of serum aspartate to alanine aminotransferase levels of less than one can distinguish NAFLD from alcoholic liver disease, but this is a nonspecific finding. Fatty infiltration imparts a diffuse echogenicity to the liver at ultrasonography, but this test cannot easily distinguish fat from fibrous tissue or identify cases of NASH. Only histological examination can establish the diagnosis of NASH, grade its severity, determine the prognosis and guide treatment.